225 related articles for article (PubMed ID: 15635025)
1. Discrepancies and interpretation problems in susceptibility testing of VIM-1-producing Klebsiella pneumoniae isolates.
Giakkoupi P; Tzouvelekis LS; Daikos GL; Miriagou V; Petrikkos G; Legakis NJ; Vatopoulos AC
J Clin Microbiol; 2005 Jan; 43(1):494-6. PubMed ID: 15635025
[TBL] [Abstract][Full Text] [Related]
2. Carbapenem resistance in Klebsiella pneumoniae not detected by automated susceptibility testing.
Tenover FC; Kalsi RK; Williams PP; Carey RB; Stocker S; Lonsway D; Rasheed JK; Biddle JW; McGowan JE; Hanna B
Emerg Infect Dis; 2006 Aug; 12(8):1209-13. PubMed ID: 16965699
[TBL] [Abstract][Full Text] [Related]
3. Comparative in vitro activity of ertapenem against extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolated in Spain.
Hernández JR; Velasco C; Romero L; Martínez-Martínez L; Pascual A
Int J Antimicrob Agents; 2006 Nov; 28(5):457-9. PubMed ID: 17008066
[TBL] [Abstract][Full Text] [Related]
4. Prevalence and contributing factors of nonsusceptibility to imipenem or meropenem in extended-spectrum β-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
Park YJ; Yu JK; Park KG; Park YG; Lee S; Kim SY; Jeong SH
Diagn Microbiol Infect Dis; 2011 Sep; 71(1):87-9. PubMed ID: 21397426
[TBL] [Abstract][Full Text] [Related]
5. Occurrence of extended-spectrum beta-lactamase in clinical isolates of Klebsiella pneumoniae in a University Hospital, Thailand.
Kusum M; Wongwanich S; Dhiraputra C; Pongpech P; Naenna P
J Med Assoc Thai; 2004 Sep; 87(9):1029-33. PubMed ID: 15516002
[TBL] [Abstract][Full Text] [Related]
6. In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniae.
Burgess DS; Hall RG
Diagn Microbiol Infect Dis; 2004 May; 49(1):41-6. PubMed ID: 15135499
[TBL] [Abstract][Full Text] [Related]
7. Effect of porins and plasmid-mediated AmpC beta-lactamases on the efficacy of beta-lactams in rat pneumonia caused by Klebsiella pneumoniae.
Padilla E; Alonso D; Doménech-Sánchez A; Gomez C; Pérez JL; Albertí S; Borrell N
Antimicrob Agents Chemother; 2006 Jun; 50(6):2258-60. PubMed ID: 16723600
[TBL] [Abstract][Full Text] [Related]
8. Activity of cefepime and carbapenems in experimental pneumonia caused by porin-deficient Klebsiella pneumoniae producing FOX-5 beta-lactamase.
Pichardo C; del Carmen Conejo M; Bernabéu-Wittel M; Pascual A; Jiménez-Mejías ME; de Cueto M; Pachón-Ibáñez ME; García I; Pachón J; Martínez-Martínez L
Clin Microbiol Infect; 2005 Jan; 11(1):31-8. PubMed ID: 15649301
[TBL] [Abstract][Full Text] [Related]
9. [Sanfetrinem, the member of trinems--in vitro activity against Klebsiella pneumoniae producing ESBL].
Wieczorek P; Sacha PT; Leszczyńska K; Jakoniuk P; Zalewska M
Med Dosw Mikrobiol; 2006; 58(1):27-32. PubMed ID: 16871970
[TBL] [Abstract][Full Text] [Related]
10. Comparison of disk diffusion, Etest and VITEK2 for detection of carbapenemase-producing Klebsiella pneumoniae with the EUCAST and CLSI breakpoint systems.
Vading M; Samuelsen Ø; Haldorsen B; Sundsfjord AS; Giske CG
Clin Microbiol Infect; 2011 May; 17(5):668-74. PubMed ID: 20649801
[TBL] [Abstract][Full Text] [Related]
11. Collateral damage of flomoxef therapy: in vivo development of porin deficiency and acquisition of blaDHA-1 leading to ertapenem resistance in a clinical isolate of Klebsiella pneumoniae producing CTX-M-3 and SHV-5 beta-lactamases.
Lee CH; Chu C; Liu JW; Chen YS; Chiu CJ; Su LH
J Antimicrob Chemother; 2007 Aug; 60(2):410-3. PubMed ID: 17576696
[TBL] [Abstract][Full Text] [Related]
12. Sources of diversity of carbapenem resistance levels in Klebsiella pneumoniae carrying blaVIM-1.
Loli A; Tzouvelekis LS; Tzelepi E; Carattoli A; Vatopoulos AC; Tassios PT; Miriagou V
J Antimicrob Chemother; 2006 Sep; 58(3):669-72. PubMed ID: 16870645
[TBL] [Abstract][Full Text] [Related]
13. Emergence of KPC-possessing Klebsiella pneumoniae in Brooklyn, New York: epidemiology and recommendations for detection.
Bratu S; Mooty M; Nichani S; Landman D; Gullans C; Pettinato B; Karumudi U; Tolaney P; Quale J
Antimicrob Agents Chemother; 2005 Jul; 49(7):3018-20. PubMed ID: 15980389
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and mechanisms of decreased susceptibility to carbapenems in Klebsiella pneumoniae isolates.
Kim SY; Park YJ; Yu JK; Kim HS; Park YS; Yoon JB; Yoo JY; Lee K
Diagn Microbiol Infect Dis; 2007 Jan; 57(1):85-91. PubMed ID: 16854555
[TBL] [Abstract][Full Text] [Related]
15. Emergence in Japan of an imipenem-susceptible, meropenem-resistant Klebsiella pneumoniae carrying blaIMP-6.
Shigemoto N; Kuwahara R; Kayama S; Shimizu W; Onodera M; Yokozaki M; Hisatsune J; Kato F; Ohge H; Sugai M
Diagn Microbiol Infect Dis; 2012 Jan; 72(1):109-12. PubMed ID: 22078906
[TBL] [Abstract][Full Text] [Related]
16. Accuracies of beta-lactam susceptibility test results for Pseudomonas aeruginosa with four automated systems (BD Phoenix, MicroScan WalkAway, Vitek, and Vitek 2).
Juretschko S; Labombardi VJ; Lerner SA; Schreckenberger PC;
J Clin Microbiol; 2007 Apr; 45(4):1339-42. PubMed ID: 17229867
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamic profiling of imipenem, meropenem and ertapenem against clinical isolates of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. from Brazil.
Kiffer CR; Kuti JL; Eagye KJ; Mendes C; Nicolau DP
Int J Antimicrob Agents; 2006 Oct; 28(4):340-4. PubMed ID: 16930951
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of 500 gram negative isolates to determine the number of major susceptibility interpretation discrepancies between the Vitek and MicroScan Walkaway for 9 antimicrobial agents.
Rittenhouse SF; Miller LA; Utrup LJ; Poupard JA
Diagn Microbiol Infect Dis; 1996 Sep; 26(1):1-6. PubMed ID: 8950521
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of antimicrobial susceptibility of bacteria containing the qnr gene and FOX-5 beta-lactamase by four automated systems.
Rodríguez-Martinez JM; Conejo MC; Martínez-Martínez L; Cano ME; Velasco C; Pascual A
Clin Microbiol Infect; 2005 May; 11(5):402-4. PubMed ID: 15819868
[TBL] [Abstract][Full Text] [Related]
20. The ongoing challenge of acquired carbapenemases: a hospital outbreak of Klebsiella pneumoniae simultaneously producing VIM-1 and KPC-2.
Zioga A; Miriagou V; Tzelepi E; Douzinas E; Tsakiri M; Legakis NJ; Daikos GL; Tzouvelekis LS
Int J Antimicrob Agents; 2010 Aug; 36(2):190-1. PubMed ID: 20510588
[No Abstract] [Full Text] [Related]
[Next] [New Search]
